{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:34:35Z","timestamp":1759178075000,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12985-018-0936-4","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T19:55:19Z","timestamp":1517255719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-\u03b1 and ribavirin for chronic hepatitis C virus infection"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Horban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Corbett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Fevery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Verbinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Jessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"936_CR1","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/hep.26641","volume":"58","author":"MW Fried","year":"2013","unstructured":"Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00eeve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918\u201329.","journal-title":"Hepatology"},{"key":"936_CR2","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","volume":"56","author":"C Moreno","year":"2012","unstructured":"Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol. 2012;56:1247\u201353.","journal-title":"J Hepatol"},{"key":"936_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van't Klooster G, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138:913\u201321.","journal-title":"Gastroenterology"},{"key":"936_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","volume":"146","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146:430\u201341.","journal-title":"Gastroenterology"},{"key":"936_CR5","volume-title":"Olysio 150 mg hard capsules. Summary of product characteristics","author":"Janssen-Cilag International NV","year":"2017","unstructured":"Janssen-Cilag International NV. Olysio 150 mg hard capsules. Summary of product characteristics. 2017. \n                    http:\/\/www.medicines.org.uk\/emc\/medicine\/28888#PHARMACOKINETIC_PROPS\n                    \n                  . Accessed 30 Jun 2017."},{"key":"936_CR6","volume-title":"Olysio\u2122 (simeprevir) US prescribing information","author":"Janssen Research & Development","year":"2017","unstructured":"Janssen Research & Development. Olysio\u2122 (simeprevir) US prescribing information 2017. \n                    http:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf\n                    \n                  . Accessed 30 Jun 2017."},{"key":"936_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730\u201340.","journal-title":"Clin Infect Dis"},{"key":"936_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486\u2013504.","journal-title":"J Hepatol"},{"key":"936_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","volume":"62","author":"O Lenz","year":"2015","unstructured":"Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in phase IIb\/III studies. J Hepatol. 2015;62:1008\u201314.","journal-title":"J Hepatol"},{"key":"936_CR10","doi-asserted-by":"publisher","unstructured":"Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, et al. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir Ther. 2017. Epub ahead of print; \n                    https:\/\/doi.org\/10.3851\/IMP3181\n                    \n                  .","DOI":"10.3851\/IMP3181"},{"key":"936_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403\u201313.","journal-title":"Lancet"},{"key":"936_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414\u201326.","journal-title":"Lancet"},{"key":"936_CR13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669\u201379.","journal-title":"Gastroenterology"},{"key":"936_CR14","doi-asserted-by":"publisher","first-page":"7548","DOI":"10.1128\/AAC.01444-15","volume":"59","author":"T Verbinnen","year":"2015","unstructured":"Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O. In vitro activity of simeprevir against hepatitis C virus genotype-1 clinical isolates and its correlation with NS3 sequence and site-directed mutants. Antimicrob Agents Chemother. 2015;59:7548\u201357.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"936_CR15","first-page":"434A","volume":"64","author":"KR Reddy","year":"2016","unstructured":"Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, et al. Long-term follow-up of patients with chronic HCV infection treated with daclatasvir-based regimens in phase 2 and 3 studies. Hepatology. 2016;64(Suppl. 1):434A.","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"936_CR16","first-page":"485A","volume":"54","author":"KE Sherman","year":"2011","unstructured":"Sherman KE, Sulkowski MS, Zoulim F, Alberti A, Wei L-J, Sullivan JC, et al. Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis from the EXTEND study. Hepatology. 2011;54(Suppl. 1):485A\u20136A.","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"936_CR17","first-page":"437A","volume":"64","author":"AJ Muir","year":"2016","unstructured":"Muir AJ, Buti M, Nahass R, Agarwal K, Gane EJ, Strasser SI, et al. Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. Hepatology. 2016;64(Suppl. 1):437A.","journal-title":"Hepatology"},{"issue":"Supp l","key":"936_CR18","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1016\/S0168-8278(16)01134-X","volume":"64","author":"E Lawitz","year":"2016","unstructured":"Lawitz E, Ruane P, Stedman C, Foster GR, Hyland RH, Coogan S, et al. Long-term follow-up of patients with chronic HCV infection following treatment with direct-acting antiviral regimens: maintenance of SVR, persistence of resistance mutations, and clinical outcomes. J Hepatol. 2016;64(Supp l):S612\u20133.","journal-title":"J Hepatol"},{"key":"936_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/apt.12350","volume":"38","author":"K Rutter","year":"2013","unstructured":"Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon-alpha2a\/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther. 2013;38:118\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"936_CR20","doi-asserted-by":"publisher","first-page":"ofw052","DOI":"10.1093\/ofid\/ofw052","volume":"3","author":"B Fevery","year":"2016","unstructured":"Fevery B, Thys K, Van Eygen V, Verbinnen T, Van Rossem E, Buelens A, et al. Pre-existence and persistence of resistant minority hepatitis C virus variants in genotype 1-infected patients treated with simeprevir\/peginterferon\/ribavirin. Open Forum Infect Dis. 2016;3:ofw052.","journal-title":"Open Forum Infect Dis"},{"key":"936_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/cid\/cit226","volume":"57","author":"JC Sullivan","year":"2013","unstructured":"Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221\u20139.","journal-title":"Clin Infect Dis"},{"key":"936_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70\u201386.","journal-title":"Gastroenterology"},{"key":"936_CR23","doi-asserted-by":"publisher","first-page":"S399","DOI":"10.1016\/S0168-8278(16)00627-9","volume":"64","author":"B Fevery","year":"2016","unstructured":"Fevery B, Vijgen L, Van Eygen V, Jessner W, Corbett C, Schlag M, et al. Consistent simeprevir resistance profile in hepatitis C virus genotype 1-infected patients failing simeprevir interferon-free compared with interferon-containing regimens [abstract]. J Hepatol. 2016;64:S399.","journal-title":"J Hepatol"},{"key":"936_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/hepr.12817","volume":"47","author":"N Morishita","year":"2016","unstructured":"Morishita N, Hiramatsu N, Oze T, Urabe A, Tahata Y, Yamada R, et al. Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection. Hepatol Res. 2016;47:773\u201382.","journal-title":"Hepatol Res"},{"key":"936_CR25","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.28491","volume":"63","author":"C H\u00e9zode","year":"2016","unstructured":"H\u00e9zode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016;63:1809\u201316.","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"936_CR26","first-page":"102A","volume":"64","author":"M Bourli\u00e8re","year":"2016","unstructured":"Bourli\u00e8re M, Gordon SC, Ramji A, Ravendhran N, Tran TT, Hyland RH, et al. Sofosbuvir\/velpatasvir\/voxilaprevir for 12 weeks as a salvage regimen in NS5A inhibitor-experienced patients with genotype 1-6 infection: the phase 3 POLARIS-1 study. Hepatology. 2016;64(Suppl. 1):102A\u20133A.","journal-title":"Hepatology"},{"key":"936_CR27","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0168-8278(17)30286-6","volume":"66","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression [abstract]. J Hepatol. 2017;66:S12.","journal-title":"J Hepatol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-0936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T19:51:04Z","timestamp":1548791464000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-018-0936-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1186\/s12985-018-0936-4","relation":{},"ISSN":["1743-422X"],"issn-type":[{"type":"electronic","value":"1743-422X"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"7 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the relevant Institutional Review Board or Independent Ethics Committee at each study centre and met the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided informed, written consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FZ has provided consulting and has participated as a speaker for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen and MSD. CM has received grant support from AbbVie, Gilead Sciences and Janssen, and has participated as a speaker or advisor for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen and MSD. SSL has received grant support and has provided consulting for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Intercept, Janssen, Merck, Novartis, Pendopharm and Roche, and has participated in a speakers bureau for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and Pendopharm. PB has participated in a speakers\u2019 bureau or advisory board for AbbVie, Bristol-Myers Squibb, Falk, Gilead Sciences, Janssen, Merz Pharma and MSD. AH has no conflicts of interest to disclose. EL has received grant support from AbbVie, Achillion Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Janssen, Merck & Co., Roche, Salix, Santaris Pharmaceuticals, Tacere and Theravance, has acted as a consultant for AbbVie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Enanta, Gilead Sciences, Janssen, Merck & Co., Novartis, Santaris Pharmaceuticals, Regulus, and Theravance, and has participated in sponsored lectures for AbbVie, Bristol-Myers Squibb, Gilead, Janssen and Merck & Co. CC, OL, BF, TV, US and WJ are employees of Janssen and may be shareholders of Johnson & Johnson.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}